ArticleScientific reports2025
Comprehensive molecular docking and antifungal activity analysis of Moringa extracts targeting Candida auris dihydrofolate reductase (8CRH).
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Candida auris is an emerging multidrug-resistant fungal pathogen posing serious global healthcare challenges due to its persistence, frequent misidentification, and resistance to all major antifungal drugs. This study aimed to explore natural therapeutic alternatives by investigating the antifungal and molecular properties of Moringa peregrina and Moringa oleifera leaf extracts. Ethanolic and aqueous extracts of both Moringa species were prepared and evaluated against C. auris and other Candida species (Candida spp.) using zone of inhibition (ZI), minimum inhibitory concentration (MIC), and minimum fungicidal concentration (MFC) assays. Phytochemical composition was characterized through fourier transform infrared spectroscopy (FTIR) and gas chromatography-mass spectrometry (GC-MS) analyses, while cytotoxicity on mammalian MCF-7 cells was assessed using the MTT assay. Molecular docking and 100-ns molecular dynamics simulations were conducted to examine the binding of key bioactive compounds to C. auris dihydrofolate reductase (DHFR; PDB: 8CRH). Ethanolic extracts exhibited the strongest antifungal activity (ZI: 16-16.5 mm; MIC: 0.5-0.7 mg/mL), whereas aqueous extracts were comparatively less effective. FTIR spectra revealed prominent peaks corresponding to hydroxyl (O-H), carbonyl (C = O), and C-O functional groups, confirming the presence of alcohols, esters, phenols, and carboxylic acids, while GC-MS identified β-sitosterol, stigmasterol, dihydroxanthin, and vitamin E derivatives as predominant constituents. Docking results revealed high binding affinities for vitamin E (- 86.6 kcal/mol) and stigmasterol (- 83.5 kcal/mol), exceeding that of fluconazole (- 27.3 kcal/mol). Molecular dynamics confirmed stable protein-ligand complexes, with hydrophobic and van der Waals forces dominating the interactions. Cytotoxicity assays revealed low toxicity at antifungal concentrations (IC₅₀ ≥ 120 µg/mL). These findings demonstrate that Moringa extracts-particularly the ethanolic fractions-harbor potent bioactive compounds with promising antifungal activity against C. auris, highlighting their potential as novel, plant-derived therapeutic candidates to combat resistant fungal infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.